FluidForm Bio, Inc. — SEC Form D Filing

FluidForm Bio, Inc. filed an SEC Form D on August 27, 2026, reporting $1.70M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
August 27, 2026
Amount reported
$1.70M
Round stage
Seed, as the amount raised of $1,703,371 is typical for early-stage biotechnology companies developing foundational technology.
Industry
Biotechnology
Website
https://www.fluidformbio.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

The pharmaceutical, medical device, and regenerative medicine industries face challenges in developing and testing new treatments and products due to the limitations of traditional tissue models and animal testing.

Solution

FluidForm Bio builds living human tissue using its FRESH 3D bioprinting technology to provide advanced models for drug discovery, device testing, and regenerative medicine applications.

Why now

Advances in 3D bioprinting technology and increasing demand for more accurate and ethical human tissue models are enabling the development of complex living tissues.

Source: SEC EDGAR Form D filing